Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Animalcare Group plc (ANCR.L)
GBp333.50
+0.00 (+0.00%)
GB LSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Unit 7, York Business Park YO26 6RB
York, GB
York, GB
CEO
Jennifer Ann Julia Winter
Website
animalcaregroup.com
IPO
2008-01-15
ISIN GB0032350695
Description
Animalcare Group plc specializes in the research, commercialization, and supply of licensed veterinary medicines and animal identification solutions. These products and services are developed for pets, livestock, and horses, serving their respective veterinary markets. The company also engages in the wholesale distribution and promotion of these specialized animal pharmaceuticals. With a broad international footprint, Animalcare Group plc caters to customers across Belgium, the Netherlands, the United Kingdom, Germany, Spain, Italy, Portugal, other European countries, Asia, the Middle East, and Africa. Established in 1972, its operations are headquartered in York, United Kingdom.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
GBp333.50
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
443.6K
Beta
0.66
Float Shares
47.71M
Free Float %
69.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.45% | +0.00% | +0.30% | +18.93% | +33.73% | +40.51% | +18.93% | +88.14% | +3.74% | +37.89% | +505.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
333.50
DCF (Unlevered)
328.05
-1.6%
DCF (Levered)
378.85
+13.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | -2 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.18
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+20.0% ★ Q4'25: +20.5% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-85.9% Q4'25: +486.8% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+12.7% Q4'25: +13.3% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+8.4% Q4'25: +8.0% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.7% Q4'25: +8.9% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+12.4% Q4'25: +14.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.91× Q4'25: 0.47× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.54M
est: 13.54M (0.0%)
|
14.70M
est: 14.70M (+0.0%)
|
15.87M
est: 15.87M (+0.0%)
|
62.29M
est: 15.87M (+292.6%)
|
72.47M
est: 85.10M (-14.8%)
|
71.12M
est: 71.10M (+0.0%)
|
70.49M
est: 70.50M (0.0%)
|
74.02M
est: 74.00M (+0.0%)
|
71.62M
est: 71.60M (+0.0%)
|
74.35M
est: 76.10M (-2.3%)
|
74.23M
est: 74.21M (+0.0%)
|
89.11M
est: 89.10M (+0.0%)
|
93.90M
93.90M – 93.90M
+5.4% YoY
|
98.80M
98.80M – 98.80M
+5.2% YoY
|
105.00M
105.00M – 105.00M
+6.3% YoY
|
111.80M
111.80M – 111.80M
+6.5% YoY
|
119.10M
119.10M – 119.10M
+6.5% YoY
|
| EBITDA |
3.44M
est: 2.11M (+63.5%)
|
3.52M
est: 2.29M (+54.1%)
|
3.32M
est: 2.47M (+34.6%)
|
9.11M
est: 2.47M (+269.2%)
|
8.66M
est: 13.22M (-34.5%)
|
8.50M
est: 5.66M (+50.1%)
|
10.30M
est: 7.84M (+31.3%)
|
10.15M
est: 11.50M (-11.7%)
|
11.04M
est: 8.39M (+31.6%)
|
11.83M
est: 12.46M (-5.1%)
|
13.43M
est: 12.15M (+10.6%)
|
16.68M
est: 14.58M (+14.3%)
|
15.37M
15.37M – 15.37M
+5.4% YoY
|
16.17M
16.17M – 16.17M
+5.2% YoY
|
17.19M
17.19M – 17.19M
+6.3% YoY
|
18.30M
18.30M – 18.30M
+6.5% YoY
|
19.49M
19.49M – 19.49M
+6.5% YoY
|
| EBIT |
3.11M
est: 599.3K (+419.0%)
|
3.19M
est: 650.6K (+390.3%)
|
2.81M
est: 702.3K (+299.7%)
|
1.00M
est: 702.3K (+42.5%)
|
280.0K
est: 3.76M (-92.6%)
|
-872.0K
est: 186.1K (-568.5%)
|
908.0K
est: -1.32M (+168.6%)
|
1.75M
est: 3.27M (-46.6%)
|
3.24M
est: -1.42M (+328.7%)
|
4.12M
est: 4.44M (-7.3%)
|
6.25M
est: 4.33M (+44.2%)
|
7.44M
est: 5.20M (+43.0%)
|
5.48M
5.48M – 5.48M
+5.4% YoY
|
5.77M
5.77M – 5.77M
+5.2% YoY
|
6.13M
6.13M – 6.13M
+6.3% YoY
|
6.53M
6.53M – 6.53M
+6.5% YoY
|
6.95M
6.95M – 6.95M
+6.5% YoY
|
| Net Income |
2.53M
est: 6.83M (-62.9%)
|
2.63M
est: 7.78M (-66.2%)
|
2.47M
est: 9.08M (-72.8%)
|
184.0K
est: 9.08M (-98.0%)
|
-222.0K
est: 7.59M (-102.9%)
|
-1.34M
est: -854.3K (-56.6%)
|
234.0K
est: -1.37M (+117.1%)
|
-77.0K
est: 7.25M (-101.1%)
|
1.97M
est: 1.16M (+68.8%)
|
1.20M
est: 5.34M (-77.5%)
|
32.22M
est: 7.42M (+334.1%)
|
5.08M
est: 10.69M (-52.5%)
|
9.58M
9.58M – 9.58M
-10.4% YoY
|
10.90M
10.90M – 10.90M
+13.8% YoY
|
14.05M
14.05M – 14.05M
+28.9% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
4.43M
est: 4.98M (-11.1%)
|
4.65M
est: 5.41M (-14.0%)
|
5.80M
est: 5.84M (-0.7%)
|
20.77M
est: 5.84M (+255.6%)
|
24.31M
est: 31.31M (-22.3%)
|
24.59M
est: 19.95M (+23.2%)
|
25.63M
est: 24.25M (+5.7%)
|
26.76M
est: 27.22M (-1.7%)
|
28.55M
est: 25.94M (+10.1%)
|
25.94M
est: 28.29M (-8.3%)
|
27.29M
est: 27.59M (-1.1%)
|
34.05M
est: 33.12M (+2.8%)
|
34.91M
34.91M – 34.91M
+5.4% YoY
|
36.73M
36.73M – 36.73M
+5.2% YoY
|
39.04M
39.04M – 39.04M
+6.3% YoY
|
41.56M
41.56M – 41.56M
+6.5% YoY
|
44.28M
44.28M – 44.28M
+6.5% YoY
|
| EPS |
0.12
est: 0.11 (+8.6%)
|
0.13
est: 0.13 (+3.2%)
|
0.12
est: 0.15 (-18.4%)
|
0.00
est: 0.15 (-97.9%)
|
0.00
est: 0.12 (-103.0%)
|
-0.02
est: 0.12 (-119.3%)
|
0.00
est: 0.10 (-96.1%)
|
0.00
est: 0.12 (-101.1%)
|
0.03
est: 0.12 (-73.2%)
|
0.02
est: 0.08 (-74.1%)
|
0.53
est: 0.11 (+395.9%)
|
0.07
est: 0.15 (-52.4%)
|
0.14
0.14 – 0.14
-10.4% YoY
|
0.16
0.16 – 0.16
+13.8% YoY
|
0.20
0.20 – 0.20
+28.9% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
23.07M
OE per share TTM
0.34
Owner's Yield
10.05%
Maintenance CapEx ratio
11.68%
Maint CapEx / Avg PPE
3.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.00% | 5.2K | 0.39% |
| 2 | Avantis International Small Cap Value ETF AVDV | 0.00% | 57.2K | 0.36% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
32.9K
Shares Outstanding
69.05M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jennifer Ann Julia Winter | Chief Executive Officer & Director | 538.0K | female |
| Christopher James Brewster | Chief Financial Officer, Company Secretary & Director | 332.0K | male |
| Carla De Schepper | Group HR Director | — | — |
| Cheryl Lawrence-Tarr | Group Head of Commercial Excellence | — | — |
| Hafid Benchaoui | Chief Strategy & Science Officer | — | — |
| Martin Gore | Director of Strategic Alliance & Acquisitions | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANCR.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
